Could a common statin boost hormone therapy in advanced breast cancer?

NCT ID NCT02958852

First seen Jun 26, 2026 ยท Last updated Jun 26, 2026

Summary

This completed Phase 2 trial tested whether adding atorvastatin (a cholesterol-lowering drug) to standard hormone therapy (letrozole or fulvestrant) could improve outcomes in 126 women with advanced, hormone-receptor-positive breast cancer. The main goal was to see if the combination increased the number of patients whose cancer shrank or stayed stable for at least 24 weeks. Researchers also tracked how long it took for the cancer to progress. The study aims to find new ways to overcome resistance to hormone therapy.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
atorvastatin (a cholesterol-lowering drug) added to standard endocrine therapy (letrozole or fulvestrant)
What this could lead to
If it works, this could point toward a way to overcome resistance to hormone therapy in advanced breast cancer, potentially extending the time the disease is controlled.
What could go wrong
This is a small Phase 2 trial (126 participants) and results may not apply to all patients. Adding atorvastatin may not improve outcomes and could cause side effects like muscle pain or liver issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Lund University Hospital, Department of Oncology

    Lund, 221 85, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.